CASI Pharmaceuticals (CASIF) Receivables (2021 - 2025)

CASI Pharmaceuticals has reported Receivables for 5 years, with the latest figure at $4.1 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables fell 73.33% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2025 stood at $4.1 million (down 73.33% YoY), and the FY2025 full-year result was $4.1 million, down 73.33% from the prior year.
• Receivables for Q4 2025 stood at $4.1 million, up from $2.6 million in the prior quarter.
• The five-year high for Receivables was $12.5 billion in Q2 2023, with the low at $2.6 million in Q3 2025.
• Historically, Receivables has averaged $3.4 billion across 5 years, with a median of $13.0 million in 2022.
• The largest YoY upside for Receivables was 125188.49% in 2025 against a maximum downside of 99.92% in 2025.
• CASI Pharmaceuticals' Receivables stood at $9.8 million in 2021, then soared by 32.34% to $13.0 million in 2022, then jumped by 78046.92% to $10.1 billion in 2023, then plunged by 99.85% to $15.3 million in 2024, then plunged by 73.33% to $4.1 million in 2025.
• The last three Receivables figures came in at $4.1 million (Q4 2025), $2.6 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.